{
 "id": "bittensor-the-intelligence-olympics/olym-f9",
 "title": "AI drug discovery, centralized vs decentralized",
 "subtitle": "Three capital-intensive AI drug discovery firms against Metanova (SN68), with scale figures as of February 2026.",
 "note": "Proprietary platforms spend hundreds of millions on internal compute. Metanova shifts that cost to miners searching a 1.75B-compound library, but it has no licensing or screening revenue yet.",
 "source": "",
 "sources": [],
 "report": {
  "title": "Bittensor: The Intelligence Olympics",
  "url": "https://www.khala.io/bittensor-the-intelligence-olympics",
  "date_published": "2026-02-19"
 },
 "url": "https://www.khala.io/bittensor-the-intelligence-olympics#ix-olym-f9-t",
 "publisher": "Khala Research",
 "cite": "Khala Research, \"AI drug discovery, centralized vs decentralized\", in \"Bittensor: The Intelligence Olympics\", February 19, 2026. https://www.khala.io/bittensor-the-intelligence-olympics#ix-olym-f9-t",
 "csv": "https://www.khala.io/data/bittensor-the-intelligence-olympics/olym-f9.csv",
 "columns": [
  "Item",
  "Scale",
  "Model",
  "Drug candidates",
  "Key partnerships",
  "Cost structure"
 ],
 "rows": [
  {
   "Item": "Recursion; Nasdaq: RXRX",
   "Scale": "Centralized; $2.1B market cap",
   "Model": "Proprietary in-house AI platform.",
   "Drug candidates": "Multiple Phase 1/2.",
   "Key partnerships": "Roche, Bayer, Nvidia, Takeda.",
   "Cost structure": "$500M+ cash burn."
  },
  {
   "Item": "Insilico Medicine; HKEX",
   "Scale": "Centralized; $293M raised in HKEX IPO",
   "Model": "End-to-end AI platform.",
   "Drug candidates": "20+ preclinical, 1 Phase 2.",
   "Key partnerships": "Sanofi, Servier ($888M), Menarini.",
   "Cost structure": "$500M+ cumulative raises."
  },
  {
   "Item": "Absci; Nasdaq: ABSI",
   "Scale": "Centralized; About $380M market cap",
   "Model": "Generative AI plus synthetic biology data engine.",
   "Drug candidates": "ABS-101 (Phase 1), ABS-201 (Phase 1/2a).",
   "Key partnerships": "AstraZeneca, Merck, AMD ($20M), Owkin.",
   "Cost structure": "About $80M a year cash usage; $64M raised Jul 2025."
  },
  {
   "Item": "Metanova (Nova); Bittensor SN68",
   "Scale": "Decentralized; Early stage, pre-revenue",
   "Model": "Decentralized miner competition on Bittensor.",
   "Drug candidates": "Wet-lab validation expected Q1 to Q2 2026.",
   "Key partnerships": "DiaGen AI (JV LOI), Yalotein Bio (MOU).",
   "Cost structure": "Near-zero compute cost, borne by $TAO-incentivized miners."
  }
 ],
 "quantitative": true
}
